Federal Register / Vol. 75, No. 223 / Friday, November 19, 2010 / Notices 70933 

Silver Spring, MD 20993–0002, 301– 

796–9001, FAX: 301–847–8533, e-mail: 

kalyani.bhatt@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), codes 

3014512529 or 3014512535. Please call 

the Information Line for up-to-date 

information on this meeting. 

Dated: November 15, 2010. 

Joanne Less, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–29280 Filed 11–18–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Cardiovascular and Renal Drugs 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). At least one portion of the 

meeting will be closed to the public. 

Name of Committee: Cardiovascular 

and Renal Drugs Advisory Committee. 

General Function of the Committees: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 8, 2010, from 8 a.m. 

to 3:30 p.m. 

Location: FDA White Oak Campus, 

Building 31, the Great Room, White Oak 

Conference Center, Rm. 1503, 10903 

New Hampshire Ave., Silver Spring, MD 

20993–0002. Information regarding 

special accommodations due to a 

disability, visitor parking and 

transportation may be accessed at: http: 

//www.fda.gov/Advisory

Committees/default.htm; under the 

heading ‘‘Resources for You’’, click on 

‘‘White Oak Conference Center Parking 

and Transportation Information for FDA 

Advisory Committee Meetings’’. Please 

note that visitors to the White Oak 

Campus must have a valid driver’s 

license or other picture ID, and must 

enter through Building 1. 

Contact Person: Elaine Ferguson, 

Center for Drug Evaluation and 

Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 31, Rm. 2417, Silver Spring, 

MD 20993–0002, 301–796–9001, FAX: 

301–847–8533, e-mail: 

elaine.ferguson@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512533. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the Agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On December 8, 2010, from 

8 a.m. to 11:30 a.m., the committee will 

discuss and provide general advice on 

the appropriate clinical study design for 

thromboxane receptor antagonists for 

prevention of cardiovascular events 

(such as heart attacks) in patients with 

aspirin intolerance due to 

immunologically-based adverse 

reactions (adverse events related to 

immune system function), specifically 

in the setting of coronary artery bypass 

grafting (also referred to as ‘‘heart bypass 

surgery’’). 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at 

http://www.fda.gov/Advisory

Committees/Calendar/default.htm. 

Scroll down to the appropriate advisory 

committee link. 

Procedure: On December 8, 2010, 

from 8 a.m. to 11:30 a.m., the meeting 

is open to the public. Interested persons 

may present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before December 6, 2010. 

Oral presentations from the public will 

be scheduled between approximately 10 

a.m. and 11 a.m. Those individuals 

interested in making formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before 

November 29, 2010. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by November 30, 2010. 

Closed Presentation of Data: On 

December 8, 2010, from 12:30 p.m. to 

3:30 p.m., the meeting will be closed to 

permit discussion and review of trade 

secret and/or confidential commercial 

information (5 U.S.C. 552b(c)(4)). 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Elaine 

Ferguson at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisory

Committees/ucm111462.htm for 

procedures on public conduct during 

advisory committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: November 15, 2010. 

Joanne Less, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–29278 Filed 11–18–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 


srobinson on DSKHWCL6B1PROD with NOTICES
70934 Federal Register / Vol. 75, No. 223 / Friday, November 19, 2010 / Notices 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cell Biology. 

Date: November 24, 2010. 

Time: 11 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call). 

Contact Person: Noni Byrnes, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5130, 

MSC 7840, Bethesda, MD 20892. (301)–435– 

1023. byrnesn@csr.nih.gov 

This notice is being published less than 

15 days prior to the meeting due to the 

timing limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Cardiac/ 

cardiovascular Signaling. 

Date: November 30, 2010. 

Time: 2:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call). 

Contact Person: Russell T Dowell, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4128, 

MSC 7814, Bethesda, MD 20892. (301) 435– 

1850. dowellr@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 15, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–29198 Filed 11–18–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center For Research 

Resources; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Research Resources Special Emphasis Panel. 

Date: February 1, 2011. 

Time: 12 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, NCRR/ 

OR, Democracy I, 6701 Democracy Blvd., 

1066, Bethesda, MD 20892. (Telephone 

Conference Call). 

Contact Person: Bonnie Dunn, PhD, 

Scientific Review Officer, Office of Review, 

National Center for Research Resources, 

National Institutes of Health, 6705 

Democracy Blvd., Dem. 1, Room 1074, MSC 

4874, Bethesda, MD 20892–4874. 301–435– 

0824. dunnbo@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research; 93.371, Biomedical 

Technology; 93.389, Research Infrastructure, 

93.306, 93.333; 93.702, ARRA Related 

Construction Awards., National Institutes of 

Health, HHS) 

Dated: November 15, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–29197 Filed 11–18–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Customs and Border Protection 

Accreditation of SEA, Ltd., as a 

Commercial Laboratory 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: Notice of accreditation of SEA, 

Ltd., as a commercial laboratory. 

SUMMARY: Notice is hereby given that, 

pursuant to 19 CFR 151.12, SEA, Ltd., 

7349 Worthington-Galena Road, 

Columbus, OH 43085, has been 

accredited to test petroleum and 

petroleum products for customs 

purposes, in accordance with the 

provisions of 19 CFR 151.12. Anyone 

wishing to employ this entity to conduct 

laboratory analyses should request and 

receive written assurances from the 

entity that it is accredited by the U.S. 

Customs and Border Protection to 

conduct the specific test requested. 

Alternatively, inquires regarding the 

specific test this entity is accredited to 

perform may be directed to the U.S. 

Customs and Border Protection by 

calling (202) 344–1060. The inquiry may 

also be sent to cbp.labhq@dhs.gov. 

Please reference the Web site listed 

below for a complete listing of CBP 

approved gaugers and accredited 

laboratories. http://cbp.gov/xp/cgov/

import/operations_support/

labs_scientific_

svcs/commercial_gaugers/. 

DATES: The accreditation of SEA, Ltd., 

as commercial laboratory became 

effective on June 22, 2010. The next 

triennial inspection date will be 

scheduled for June 2013. 

FOR FURTHER INFORMATION CONTACT: 

Anthony Malana, Laboratories and 

Scientific Services, U.S. Customs and 

Border Protection, 1300 Pennsylvania 

Avenue, NW., Suite 1500N, 

Washington, DC 20229, 202–344–1060. 

Dated: November 8, 2010. 

Ira S. Reese, 

Executive Director, Laboratories and 

Scientific Services. 

[FR Doc. 2010–29177 Filed 11–18–10; 8:45 am] 

BILLING CODE 9111–14–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Accreditation and Approval of Intertek 

USA, Inc., as a Commercial Gauger 

and Laboratory 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: Notice of accreditation and 

approval of Intertek USA, Inc., as a 

commercial gauger and laboratory. 

SUMMARY: Notice is hereby given that, 

pursuant to 19 CFR 151.12 and 19 CFR 

151.13, Intertek USA, Inc., 327 Erickson 

Ave., Essington, PA 19029, has been 

approved to gauge and accredited to test 

petroleum and petroleum products for 

customs purposes, in accordance with 

the provisions of 19 CFR 151.12 and 19 

CFR 151.13. Anyone wishing to employ 

this entity to conduct laboratory 

analyses and gauger services should 

request and receive written assurances 

from the entity that it is accredited or 

approved by the U.S. Customs and 

Border Protection to conduct the 

specific test or gauger service requested. 

Alternatively, inquires regarding the 

specific test or gauger service this entity 

is accredited or approved to perform 

may be directed to the U.S. Customs and 

Border Protection by calling (202) 344– 

1060. The inquiry may also be sent to 

cbp.labhq@dhs.gov. Please reference the 

Web site listed below for a complete 


srobinson on DSKHWCL6B1PROD with NOTICES